Company Overview

SYNERGY PHARMACEUTICALS INC. (NASDAQ: SGYP)

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.

We have pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders.  We discovered, are developing and control 100% worldwide rights to our proprietary uroguanylin based GI platform that includes one commercial product, TRULANCE™ (plecanatide), and a second lead product candidate, dolcanatide.

We are based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Synergy [SGYP] became a public company in July 2008 and is currently listed on NASDAQ.

Stock Information

SGYP

NASDAQ

Volume

Market Cap

Change

Day High

Day Low

Events

Upcoming Event

Synergy Pharmaceuticals 2017 Annual Meeting

Jun 27, 2017 • 9:00AM EDT

Archived Event

Jefferies 2017 Global Healthcare Conference

Jun 8, 2017 • 2:00PM EDT

Webcast

Archived Event

Synergy Pharmaceuticals Q1 2017 Financial Results

May 10, 2017 • 4:30PM EDT

View All Events